Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs PAGSEG Inc (PAGS) Price & Performance

Citius Pharmaceuticals IncTrade
PAGSEG IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs PAGSEG Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while PAGSEG Inc trades at $8.66 (market cap $2.48B). The key difference: PAGSEG Inc is far larger — about 123.9× Citius Pharmaceuticals Inc's market cap, and PAGSEG Inc pays a 11.7% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRPAGS
Market Cap
$20.01M$2.48B
Sector
HealthTechnology
52-Week High
$1.82$12.00
52-Week Low
$0.48$8.38
Enterprise Value
$16.23M$10.22B
Dividend Yield
11.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

PAGSEG Inc

PAGS trades at $8.59, down 5.4% in the last session, with a bearish technical signal despite attractive valuation metrics (P/E 6.17, P/S 0.64). The company reported $20.41B revenue and $2.12B net income for 2025, maintaining stable profitability with a 10.4% net margin. Recent Q2 2026 earnings beat expectations with EPS of $0.41 versus $0.389 expected, while analyst consensus remains bullish with a $11.45 price target.

The stock presents a value opportunity given its discounted valuation and strong analyst support (62.5% buy ratings), but faces headwinds from technical weakness and competitive pressures in Brazil's digital banking sector. Upside potential exists if earnings momentum continues, though investors should monitor execution risks and macroeconomic conditions affecting Brazilian financial markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About PAGSEG Inc

PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.

Read more on PAGS